Platform Technology
Clinical Data
Revolutionizing Cancer Treatment
Transforming the future of cancer treatment with a next generation ADC platform that will bring new hope to patients worldwide.
Mayo Clinic has created a transformative, next-generation antibody-drug conjugate (ADC) platform, validated by human clinical proof of concept data.
The Challenge in Current ADC Therapy
The Delivery Dilemma
Existing antibody-drug conjugates face a critical limitation: delivering sufficient therapeutic doses to cancer cells while minimizing harmful exposure to healthy tissues. This narrow therapeutic window has constrained the potential of ADC technology and limited treatment options for patients with aggressive cancers.
Our Solution
ADNIC Therapeutics, a research effort led by Dr. Svetomir Markovic, MD, PhD, has developed a first-in-class modular platform that fundamentally reimagines ADC design. Our Antibody-Drug NanoImmuno Conjugate (ADNIC) technology achieves unprecedented drug loading while maintaining favorable safety profiles.
The ADNIC Platform Technology
The ADNIC (Antibody-Drug Nanoparticle Immunoconjugate) platform represents a sophisticated evolution in targeted drug delivery for oncology therapeutics. This tripartite nanostructure integrates three critical functional components into a single biocompatible delivery system designed to maximize therapeutic efficacy while minimizing systemic toxicity.
Cytotoxic Core
The particle's interior houses small-molecule cytotoxic agents—potent chemotherapeutic compounds that disrupt cellular division and induce apoptosis in malignant cells. This encapsulation strategy protects healthy tissue during circulation.
Albumin Shell
A biocompatible albumin matrix surrounds the cytotoxic core, providing structural integrity and enhanced biodistribution properties. Albumin naturally accumulates in tumor microenvironments via the enhanced permeability and retention effect.
Antibody Corona
Tumor-targeting antibodies attach to the albumin surface and enable active targeting of cancer-specific targets. This immunological guidance system directs the nanoparticle preferentially to cancer cells, improving the ratio of cytotoxic 100-fold over traditional ADC's.
Core Encapsulation
Cytotoxic agent sequestered within albumin matrix through proprietary ratios and encapsulation chemistry
Surface Functionalization
Antibody binds to the albumin via stable non-covalent linkages that preserve antigen-binding activity, eliminating complex conjugation chemistry
Tumor Recognition
Receptor-mediated endocytosis is triggered by the antibody-antigen binding at tumor cell surface which releases the cytotoxic agent. Additionally, albumin binding to gp60 and SPARC facilitates trans-endothelial transport and enhanced uptake of drug payload by tumor cells
Intracellular Release
pH-dependent or enzymatic degradation releases cytotoxic payload within cancer cells
The ADNIC architecture leverages decades of nanoparticle research to overcome the limitations of conventional antibody-drug conjugates. By utilizing albumin as both a structural scaffold and a natural tumor-homing mechanism, combined with the targeting precision of therapeutic antibodies, this platform achieves dual-mode targeting. The result is a next-generation delivery system with enhanced tumor accumulation, improved safety profiles, and the potential to deliver higher cytotoxic payloads than traditional ADC formats.
Compelling Clinical Evidence
37-80%
Objective Response Rates
Across multiple Phase 1b studies in metastatic ovarian, endometrial cancers, and non-Hodgkin's lymphomas
100x
Drug Loading Capacity
Drug-to-antibody ratio far exceeds traditional ADC platforms, enabling more potent therapeutic delivery
3
FDA-Cleared INDs
Three Investigational New Drug applications have been FDA cleared, validating the clinical potential
Multiple Phase 1b studies completed at Mayo Clinic demonstrate consistent efficacy across diverse tumor types, establishing ADNIC as a versatile and promising new therapeutic platform.
Demonstration of Platform Viability
The ADNIC platform's versatility and efficacy have been proven across multiple preclinical and clinical applications, highlighting its potential for a broad range of oncology indications.
AR160: Anti-CD20 Conjugate
  • Achieved superior efficacy in a mouse model of lymphoma.
  • Prototype demonstrated 80% Objective Response Rate (ORR) in lymphoma patients in Mayo Clinic clinical studies.
AP160: Anti-PDL1 Conjugate
  • Showed superior efficacy in a mouse model of human Triple-Negative Breast Cancer (TNBC).
Dual Chemotherapeutic Conjugates
  • Successfully formed conjugates with two chemotherapeutics: albumin-coated paclitaxel and oxaliplatin nanoparticles with a targeting antibody.
These examples underscore the platform's modularity and viabilty to enhance various therapeutic agents, opening avenues for next-generation treatments.
Safety Profile
Early Safety & Tolerability
The ADNIC platform leverages compounds with well-established safety profiles, including components similar to Abraxane. As an example, clinical data demonstrate a similar safety profile to Abraxane with a signficant reduction in grade 3–4 sensory adverse events.
This favorable safety profile enables higher effective doses to be delivered to tumors while maintaining patient quality of life - a critical advantage in treating aggressive metastatic cancers.
Platform Advantages
Pipeline in a Platform
Modular design enables rapid development of multiple therapeutic candidates. Next-generation approaches with dual toxic payloads or multiple targeting antibodies are currently in development.
Simplified Manufacturing
Non-covalent drug binding eliminates complex conjugation chemistry, reducing production costs and timelines.
De-risked Development
Utilizes FDA-approved components with known pharmacology, significantly reducing clinical development risk.
Broad IP Protection
32 issued patents provide extensive global coverage, revitalizing target antibodies and cytotoxic agents.
Robust Intellectual Property Portfolio
32
Patents Issued
Comprehensive global protection across platform technology and specific applications
5
Peer-Reviewed Publications
Strong scientific foundation with published clinical and preclinical data
3
Conference Presentations
Abstracts and posters demonstrating platform versatility and clinical promise
Our extensive IP estate creates multiple barriers to competition while enabling strategic partnerships and licensing opportunities across oncology indications.
Pipeline Overview
Our advanced pipeline leverages the ADNIC platform's versatility, and selects a high probability lead program (AT-201) and two additional programs ready that are clinical trial ready once GMP material is available.
AT-201, our lead candidate, has successfully completed Phase 1b trials utilizing a model compound AB160 manufactured in Mayo Clinic's compounding pharmacy. AP160 has an approved IND and is ready for clinical development once GMP AT-202 CMC package is complete. AR160 IND was approved for nab-paclitaxel + anti-CD20 in lymphoma as a proof of concept with 80% ORR, leading to the AT-203 (CD3) program targeting high unmet need indications.
Next Generation Concepts
The ADNIC platform's modular design enables innovative therapeutic approaches that address limitations of current treatment modalities. These next-generation concepts are being developed by Mayo Clinic and demonstrate the platform's potential as an alternative next generation application.
CAR-T Alternative: Anti-CD3 Conjugate
  • ADNIC offers an alternative approach to CAR-T therapy, combining nab-paclitaxel with anti-CD3.
  • No CART available for T-Cell Lymphoma.
  • Advantages include reduced manufacturing complexity and broader patient accessibility compared to traditional CAR-T.
Bi-specific Antibody Alternative
  • ADNIC could combine a chemotherapy agent with bi-specific antibodies for enhanced targeting.
  • This approach has potential to improve targeting and reduced systemic toxicity compared to traditional combination therapies.
Dual Chemotherapeutic Conjugates
  • Mayo Clinic has successfully formed conjugates with two chemotherapeutics: albumin-coated paclitaxel and oxaliplatin nanoparticles with a targeting antibody.
  • Demonstrates the platform's ability to deliver multiple therapeutic agents simultaneously.
These innovative applications underscore the ADNIC platform's potential to transform cancer treatment by offering more effective, accessible, and versatile alternatives to existing therapeutic modalities.
Peer Reviewed Publications
Our scientific rigor and groundbreaking research are documented in several peer-reviewed publications, abstracts, and conference posters, underscoring the ADNIC platform's validation and scientific merit.
Peer-Reviewed Publications
  • Nature Scientific Reports 2017: Identification of a Peptide-Peptide Binding Motif in the Coating of Nab-Paclitaxel Nanoparticles with Clinical Antibodies: Bevacizumab, Rituximab, and Trastuzumab
Abstracts
  • LS1681 ASH 2023 Abstract: A First in Human Phase I Trial (LS1681) of Abraxane®/Rituximab 160 nm nanoparticle (AR160) in Relapsed Refractory B-Cell Lymphomas Including Transformed Follicular Lymphoma: A Final Report
  • LS1681 ASCO 2020 Abstract: A Phase I Trial of AR160 (Abraxane/Rituximab 160nm nanoparticle) in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL) Including Transformed Follicular Lymphoma
Poster Presentations
  • AB-160 ASCO 2023: A Phase 1 Trial of Nab-Paclitaxel and Bevacizumab (AB160) Nano-Immunocongugate Therapy for Metastatic Gynocological Malignancies: MC1371 (NCT02020707)
Our Team
ADNIC Therapeutics is driven by a visionary team of scientific and clinical development experts committed to revolutionizing cancer treatment through targeted nanomedicine.
Svetomir N. Markovic, M.D., Ph.D.
Inventor, Program Leader
Dr. Svetomir N. Markovic, M.D., Ph.D., is a distinguished physician-scientist and the inventor behind ADNIC Therapeutics. At Mayo Clinic, Dr. Markovic leads the Melanoma Research Laboratory, where his team focuses on translational immunotherapeutics - developing novel cancer vaccines, immune-boosting agents, and nanomedicines to more precisely target metastatic melanoma and other malignancies.
He is the Charles F. Mathy Professor of Melanoma Research and has received the Mayo Clinic Distinguished Inventor Award, recognizing his innovative contributions to cancer therapy. Dr. Markovic is deeply committed to translating scientific insight into safer, more effective treatments - driving ADNIC’s mission to leverage precision immunotherapy for unmet oncologic needs.
Wendy K. Nevala, M.S.
Key Scientific Leader
Wendy Nevala is a pivotal scientific leader for ADNIC, collaborating closely with Dr. Markovic in the Mayo Clinic Melanoma Research Laboratory. Her expertise in immunology and translational research is critical to developing targeted therapies like antibody-directed chemotherapy, propelling ADNIC’s drug development pipeline from initial concept to clinical readiness. She has authored or co-authored over 100 scientific publications.
Jill Schimke, M.S.
Project Manager
Jill Schimke brings extensive project leadership and operational expertise from her background in healthcare and research, including previous roles at Mayo Clinic. With a Master of Science and a strong scientific foundation in immunology and nanomedicine research, Jill is instrumental in coordinating clinical programs across Mayo Clinic, and orchestrating ADNIC’s R&D programs and cross-functional initiatives.
Liyi Geng, Ph.D.
Senior Research Technologist
Dr. Liyi Geng is an accomplished translational scientist with more than two decades of experience in gene therapy, viral vector engineering, and preclinical model development. His work has contributed to multiple breakthrough programs involving AAV-based delivery of therapeutic enzymes and CNS–targeted biologics.
With a portfolio of 25+ peer-reviewed publications and a strong track record supporting first-in-human therapeutic concepts, Dr. Geng brings deep technical expertise to ADNIC Therapeutics' clinical development programs.
Transforming Cancer Care
ADNIC Therapeutics is poised to redefine the ADC landscape with a novel platform designed to deliver superior efficacy, favorable safety, and manufacturing efficiency—addressing critical unmet needs in oncology while creating substantial value for patients, clinicians, and investors.
Disclaimers
FORWARD-LOOKING STATEMENTS
This presentation contains forward-looking statements regarding ADNIC Therapeutics' business, financial condition, results of operations, and prospects. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions identify forward-looking statements. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. ADNIC Therapeutics undertakes no obligation to update any forward-looking statements.
DISCLAIMERS
YOU UNDERSTAND AND AGREE THAT THIS SITE AND ANY SERVICES, CONTENT, OR INFORMATION CONTAINED ON OR PROVIDED BY THIS SITE IS PROVIDED ON AN "AS IS" BASIS. ADNIC THERAPEUTICS DOES NOT MAKE ANY EXPRESS OR IMPLIED WARRANTIES, REPRESENTATIONS, OR ENDORSEMENTS WHATSOEVER (INCLUDING WITHOUT LIMITATION WARRANTIES OF TITLE OR NONINFRINGEMENT OR THE IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE) WITH REGARD TO THE SERVICE OR ANY INFORMATION PROVIDED THROUGH THE SERVICE.
ACCURACY AND INTEGRITY OF INFORMATION
Although ADNIC Therapeutics attempts to ensure the integrity and accuracy of the Site, it makes no representations, warranties, or guarantees whatsoever as to the correctness or accuracy of the Site and content thereon. It is possible that the Site could include typographical errors, inaccuracies, or other errors. In the event that an inaccuracy arises, please inform ADNIC Therapeutics so that it can be corrected. Information contained on the Site may be changed or updated without notice.
LIMITATIONS OF LIABILITY
THE USE OF THE SITE IS ENTIRELY AT YOUR OWN RISK, AND IN NO EVENT SHALL ADNIC THERAPEUTICS BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, PUNITIVE, OR ANY OTHER MONETARY OR OTHER DAMAGES, FEES, FINES, PENALTIES, OR LIABILITIES ARISING OUT OF OR RELATING IN ANY WAY TO THIS SERVICE, OR SITES ACCESSED THROUGH THIS SERVICE, AND/OR CONTENT OR INFORMATION PROVIDED HEREIN.
LINKS TO THIRD PARTY WEBSITES
The Site contains links to other sites operated by third parties. These links are available for your convenience and are intended only to enable access to these third party sites. ADNIC Therapeutics does not warrant or make any representation about the substance, quality, functionality, accuracy, fitness for a particular purpose, merchantability or any other representation about any third party site or its content. A link to a third party site does not constitute sponsorship, endorsement, approval, or responsibility for any third party site.